Contact
searchSearch
HMP Global
Login
Test Your Knowledge

Quiz: Do Low-Dose TKIs Prior to Therapy Cessation Impair CML Remission Rates?

08/19/2020

Recent News

News
Anti T-Lymphocyte Globulin Remains Standard GVHD Prophylaxis Following Unrelated Donor Transplantation
06/16/2026
Emily Estrada
Results from a phase 3 trial demonstrated that post-transplant cyclophosphamide did not achieve noninferiority to anti–T-lymphocyte globulin for overall survival following unrelated donor alloHCT in patients with high-risk myeloid...
Results from a phase 3 trial demonstrated that post-transplant cyclophosphamide did not achieve noninferiority to anti–T-lymphocyte globulin for overall survival following unrelated donor alloHCT in patients with high-risk myeloid...
Results from a phase 3 trial...
06/16/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Significantly Improves Outcomes in Heavily Pretreated Relapsed or Refractory Multiple Myeloma
06/16/2026
Emily Estrada
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2...
06/16/2026
Oncology
News
In Vivo CAR T-Cell Therapy Shows Encouraging Early Activity in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
06/16/2026
Emily Estrada
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.
Results from an ongoing phase 1...
06/16/2026
Oncology
News
Gilteritinib Fails to Improve OS in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
06/16/2026
Emily Estrada
Results from the phase 3 HOVON156/AMLSG28-18/PASHA trial demonstrated that gilteritinib did not significantly improve overall survival compared with midostaurin when combined with intensive chemotherapy in patients with newly diagnosed...
Results from the phase 3 HOVON156/AMLSG28-18/PASHA trial demonstrated that gilteritinib did not significantly improve overall survival compared with midostaurin when combined with intensive chemotherapy in patients with newly diagnosed...
Results from the phase 3...
06/16/2026
Oncology
News
Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Emerges as Potential New Standard in Relapsed or Refractory Chronic Lymphocytic Leukemia
06/16/2026
Stephanie Holland
Results from the phase 3 BRUIN CLL-322 trial demonstrated that pirtobrutinib plus venetoclax and rituximab significantly improved outcomes compared with venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia.
Results from the phase 3 BRUIN CLL-322 trial demonstrated that pirtobrutinib plus venetoclax and rituximab significantly improved outcomes compared with venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia.
Results from the phase 3 BRUIN...
06/16/2026
Oncology
News
Switchable Allogeneic CAR T-Cell Therapy Shows Early Promise in Relapsed or Refractory Acute Myeloid Leukemia
06/16/2026
Emily Estrada
Results from the phase 1a RevSTAR-123 study demonstrated that an investigational switchable allogeneic CD123-directed CAR T-cell therapy showed encouraging clinical activity in heavily pretreated relapsed or refractory acute myeloid leukemia.
Results from the phase 1a RevSTAR-123 study demonstrated that an investigational switchable allogeneic CD123-directed CAR T-cell therapy showed encouraging clinical activity in heavily pretreated relapsed or refractory acute myeloid leukemia.
Results from the phase 1a...
06/16/2026
Oncology
News
CD5 Inhibition Enhances Activity of T-Cell Engagers Across Tumor Types
06/16/2026
Stephanie Holland
Results from a translational study identified CD5 as a key negative regulator of T-cell engager activity and suggest that CD5 inhibition may enhance responses to multiple CD3-engaging therapies.
Results from a translational study identified CD5 as a key negative regulator of T-cell engager activity and suggest that CD5 inhibition may enhance responses to multiple CD3-engaging therapies.
Results from a translational...
06/16/2026
Oncology
News
Talquetamab-Based Regimens Improve Survival in Relapsed or Refractory Multiple Myeloma
06/16/2026
Stephanie Holland
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3...
06/16/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Emerges as Potential New Standard in High-Risk Diffuse Large B-Cell Lymphoma
06/15/2026
Stephanie Holland
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3 frontMIND trial demonstrated that tafasitamab plus lenalidomide and R-CHOP significantly improved PFS outcomes in previously untreated patients with high-risk diffuse large B-cell lymphoma or high-grade B-cell...
Results from the phase 3...
06/15/2026
Oncology
News
Blinatumomab Improves Survival and Reduces Toxicity in Pediatric Patients With High-Risk B-Acute Lymphoblastic Leukemia
06/15/2026
Stephanie Holland
Results from a phase 2 study demonstrated that replacing 2 intensive chemotherapy courses with blinatumomab improved outcomes and reduced treatment-related toxicity in newly diagnosed pediatric patients with high-risk B-cell acute...
Results from a phase 2 study demonstrated that replacing 2 intensive chemotherapy courses with blinatumomab improved outcomes and reduced treatment-related toxicity in newly diagnosed pediatric patients with high-risk B-cell acute...
Results from a phase 2 study...
06/15/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use